At the European Society for Medical Oncology congress, the American pharmaceutical company Johnson & Johnson unveiled promising results for its prostate cancer drug candidate.
According to an early-stage clinical trial, JNJ-6143 significantly reduced tumors in patients with advanced prostate cancer who had already received multiple therapies.
Administered orally once daily, this treatment is based on an innovative approach that targets a protein essential for cancer cell survival in order to selectively eliminate them.
The study focused on a daily dose of 50 mg. Among the 31 patients evaluated, 77% experienced a decrease of at least 50% in their PSA levels, an indicator used to monitor the progression of prostate cancer. A decrease of at least 90% was observed in 48% of them. Imaging studies also confirmed these results: 69% of patients with measurable tumors achieved a complete or partial response.
For Johnson & Johnson, this drug candidate expands its therapeutic arsenal against prostate cancer with a novel mechanism of action. The most frequent side effects observed during the trial were nausea and an increase in cholesterol and triglycerides. Only one patient discontinued treatment due to adverse effects.
The pharmaceutical group acquired the rights to this molecule through its acquisition of Halda Therapeutics, finalized last year for $3.05 billion.
 Pascal Lemontel
|
26/10/2026 | 
Anglais
Arabic
Deutsch
Français
Español
Italien
Português
Russian